Open access
Nov 2026
Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group.
Relapsed B-acute lymphoblastic leukemia (B-ALL) generally occurs due to the emergence of subclones resistant to therapy, leading to poor outcome. Here, we describe novel genomic alterations responsible for therapeutic resistance at a subtype level in a clinical trial (AALL1331) which randomized patients to blinatumomab...
Yuan Feng, Han-Xia Li, H. Mulder et al.
· Blood · 0 citations